Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin.

Biomolecules - 25 Aug 2021

Huang Kuo-Yen, Wang Tong-Hong, Chen Chin-Chuan, Leu Yann-Lii, Li Hsin-Jung, Jhong Cai-Ling, Chen Chi-Yuan

Abstract excerpt

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are approved treatments for non-small-cell lung cancer (NSCLC) patients harboring activating EGFR mutations. The EGFR C797S mutation is one of the known acquired-resistance mutations to the latest third-generation TKIs. At present, there are no clear options for treating patients who acquire resistance to third-generation TKIs. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy
Share to Axl Receptor Tyrosine Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clone Cells

Share to Mice, Nude

Share to Organophosphorus Compounds

Share to Pyrimidines

Share to Quercetin

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 34572484
DOI: 10.3390/biom11091271
PMCID: PMC8470952

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin.PMID 34572484Read ↗

Identification of a novel nitroflavone-based scaffold for designing mutant-selective EGFR tyrosine kinase inhibitors targeting T790M and C797S resistance in advanced NSCLC.Semantic proximity Read ↗

Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancerSemantic proximity Read ↗

Discovery of potent and effective inhibitors containing sulfoxide structures targeting EML4-ALK rearrangement and EGFR mutant non-small cell lung cancer.Semantic proximity Read ↗

Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)-7-methoxyquinazoline derivatives as dual EGFR/c-Met inhibitors for the treatment of NSCLC.Semantic proximity Read ↗

Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization.Semantic proximity Read ↗

Novel bioactive 2-phenyl-4-aminopyrimidine derivatives as EGFRDel19/T790M/C797S inhibitors for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

EGFR suppression contributes to growth inhibitory activity of G-quadruplex ligands in non-small cell lung cancers.Semantic proximity Read ↗

Coccinic acid exhibits anti-tumor efficacy against NSCLC harboring EGFR L858R/T790M mutation via the EGFR/STAT3 pathway.Semantic proximity Read ↗

Hyperoside exhibits anticancer activity in non‑small cell lung cancer cells with T790M mutations by upregulating FoxO1 via CCAT1.Semantic proximity Read ↗

Inhibitory effect of 1,4,5,6-tetrahydroxy-7,8-diprenylxanthone against NSCLC with L858R/T790M/C797S mutant EGFR.Semantic proximity Read ↗

Parthenolide inhibits the growth of non-small cell lung cancer by targeting epidermal growth factor receptorSemantic proximity Read ↗

Oxymatrine inhibits non-small cell lung cancer via suppression of EGFR signaling pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.